Virtual | October 6-8, 2026
TUESDAY, OCTOBER 6, 2026
8:00 AM – 10:30 AM
SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
10:30 AM – 1:30 PM
SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
1:30 PM – 3:00 PM
LUNCH BREAK
3:00 PM – 3:40 PM
KEYNOTE PRESENTATIONS
3:40 PM – 6:00 PM
PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
WEDNESDAY, OCTOBER 7, 2026
8:00 AM – 10:30 AM
SESSION II (PART 1). CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
10:30 AM – 12:50 PM
SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
12:50 PM – 2:15 PM
LUNCH BREAK
2:15 PM – 6:30 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
THURSDAY, OCTOBER 8, 2026
8:00 AM – 12:30 PM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
12:30 PM – 1:00 PM
GENERAL DISCUSSION
1:00 PM – 2:00 PM
LUNCH BREAK
2:00 PM – 2:30 PM
KEYNOTE PRESENTATION
2:30 PM – 3:00 PM
PRESENTATION OF WINNING ABSTRACTS
3:00 PM – 4:00 PM
GENERAL DISCUSSION
4:00 PM
ADJOURN
.8:15 am SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Peter Albers, MD, Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ), Heidelberg University, Germany
Sigrid Carlsson, MD, PhD, MPH, Division Head, Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg University, Germany
Stenio Zequi, MD, MSc, PhD, Head of Referral Center for Urological Tumors, A.C. Camargo Cancer Center, Brazil
8:30 am Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening
8:30 am Topic 1A: Advancing Risk-Stratified Screening and Early Detection
Sigrid Carlsson, MD, PHD, MPH
8:40 am Q & A
8:42 am Topic 1B: Update on the PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)
Peter Albers, MD
8:52 am Q & A
8:54 am Topic 1C: Overview and Update on ERSPC, PIAS, and PRAISE-U Clinical Trials
Roderick CN van den Bergh, MD, PhD, Department of Urology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands
9:04 am Topic 1D: Organized Prostate Testing (OPT) in Sweden
Anders Bjartell, MD, PhD, FEBU, Professor in Urology, Department of Translational Medicine, Lund University; and Senior Consultant, Skane University Hospital, Sweden
9:14 am Q & A
9:16 am Topic 1E: Update on TRANSFORM – National UK Trial of Prostate Cancer Screening
Rhian Gabe, PhD, Professor of Biostatistics and Clinical Trials, Director of Barts Clinical Trials Units, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom
9:26 am Q & A
9:28 am Topic 1F: Update on PROSCREEN: A Randomized Population-Based Screening Trial Combining PSA, Kallikrein Panel and MRI
Anssi Auvinen, MD, PhD, Professor and Head, Department of Epidemiology, Tampere University, Finland
9:38 am Q & A
9:40 am – 10:00 am Panel Discussion: “Smart” Prostate Cancer Screening
10:00 am – 10:30 am COFFEE BREAK
10:30 am SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Preston Sprenkle, MD, Associate Professor of Surgery, Yale University School of Medicine; and Vice Chair, NCCN Prostate Cancer Early Detection Panel
Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Scientific Director of Clinical and Translational research MGB, Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Immediate Past Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS
10:30 am Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
10:30 am Topic 2A: Current and Emerging Liquid Diagnostics
10:30 am Overview of Liquid Biomarkers
E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal
10:40 am Q & A
10:42 am Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and In Combination with Mutli-Parametric MRI for the Detection of High-Grade Prostate Cancer
Mark Stovsky, MD, MBA, FACS, Chief Medical Officer, Cleveland Diagnostics, Inc.
10:48 am Q & A
10:50 am Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies
10:50 am OPTIMUM Trial – A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer
Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation
11:00 am Q & A
11:02 am MRI PI-RADS Standardization and Clinical Evaluation
Clare M. C.Tempany-Afdhal, MB, BAO, BCh
11:12 am Q & A
11:14 am Towards Reproducible Prostate MRI Across Scanners and Sites: Preliminary Clinical Evidence for Concurrent ADC Calibration Using METRION
Xavier Golay, PhD, MS, Honorary Professor of MRI Physics, University College London, UK
11:24 am Q & A
11:26 am Topic 2C: State of the Art and Future Directions in Prostate Biopsies
11:26 am Urologic Perspective
Alastair Lamb, MD, PhD, FRCS, CRUK Advanced Clinician Scientist Fellow, Barts Cancer Institute, Queen Mary University of London; Honorary Consultant Urological Surgeon, Guy’s Hospital; and Visiting Associate Professor, University of Oxford, United Kingdom (TBC)
11:36 am Q & A
11:38 am Role of MRI-Targeted Biopsy in Optimizing Prostate Cancer Diagnosis
Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
11:48 am Q & A
11:50 am Topic 2D: Do Biopsies Account for Some of the Progression We See After Prostate Cancer Treatments?
Mark Emberton, MD, Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom
12:00 pm Q & A
12:02 pm – 12:30 pm Panel Discussion: Current and Emerging Diagnostic Tools
12:30 pm Topic 3: Newly Identified Mutations Associated with Prostate Cancer Risk and Aggressiveness
Brian T. Helfand, MD, PhD, Ronald L. Chez Family and Richard Melman Family Endowed Chair in Prostate Cancer, and Clinical Professor, University of Chicago, Pritzker School of Medicine, NorthShore University HealthSystem, Endeavor Health
12:40 pm Q & A
12:42 pm Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer
Preston Sprenkle, MD
12:52 pm Q & A
12:54 pm – 1:30 pm General Discussion – Moderators and Speakers
1:30 pm – 3:00 pm LUNCH BREAK
3:00 pm KEYNOTE PRESENTATIONS
3:00 pm NCCN Guidelines for Prostate Cancer Treatment
Mack Roach III MD, FACR, FASTRO, FASCO, Professor of Radiation Oncology and Urology and Director, Particle Therapy Research Program & Outreach, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
.
3:15 pm Q & A
3:20 pm Precision Care and Health Disparities in Black Men
Adam B Murphy, MD, MBA, MSCI, Distinguished Professor of Population Health Research in Urology, Department of Urology and Preventive Medicine, Northwestern Medicine – Feinberg School of Medicine
.
3:35 pm Q & A
3:40 pm PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
Moderators:
Paul Boutros, PhD, MBA, Professor of Cancer Genetics & Epigenetics and Director, Cancer Center; and Vice President, Data Science & AI, Sanford Burnham Prebys Medical Discovery Institute
.
Amita Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center
.
3:50 pm The Evolution of AI Tooling: Should I Be Scared Yet?
Paul Boutros, PhD, MBA
4:00 pm Q & A
4:02 pm AI, Bioinformatics and Prostate Cancer Care
Ilya Gipp, MD, PhD, Chief Medical Officer – Oncology, GE Healthcare, Sponsored by GE Healthcare (TBC)
4:12 pm Q & A
4:14 pm AI for MR Scanning and Disease Prediction
Angela Tong, MD, Abdominal Radiologist, New York University Grossman School of Medicine
4:24 pm Q & A
4:26 pm Racially-Associated MRI Analysis and Modeling for Predicting Aggressive Prostate Cancer
Kyung Sung, PhD, Professor of Radiological Sciences, Magnetic Resonance Research Labs, David Geffen School of Medicine, University of California, Los Angeles
4:36 pm Q & A
4:38 pm AI in Surgery and Pathology for Prostate Cancer
Saad Nadeem, PhD, Associate Attending Computer Scientist, Department of Medical Physics, Memorial Sloan Kettering Cancer Center
4:48 pm Q & A
4:50 pm AI and Multi-Modality Diagnostics for Prostate Cancer
Francisco Sanchez-Vega, PhD, Assistant Attending, Computational Oncology Service, Department of Epidemiology and Biostatistics; and Head of Real-World Data Analysis, Halvorsen Center for Computational Oncology, Memorial Sloan Kettering Cancer Center
5:00 pm Q & A
5:02 pm – 5:30 pm Panel Discussion: Moderators, Speakers
5:30 pm – 6:00 pm GENERAL DISCUSSION
8:00 am SESSION II (PART 1). CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Mohammed Shahait, MD, Assistant Professor of Clinical Urology, Department of Urology, University of California, Irvine
Lalitha K. Shankar, Acting Associate Director, Cancer Imaging Program; and Chief, Clinical Trials Branch, National Cancer Institute, National Institutes of Health
8:05 am Topic 1: Multiomics of Prostate Cancer
8:05 am Topic 1A: Prostate Cancer Imaging
8:05 am PRIMARY2 Clinical Trial – PSMA PET/CT as a “Manogram” to Improve Prostate Cancer Diagnosis
Professor Michael Hofman, MBBS, FRACP, FAANMS, FICIS, FSNNMI, FAHMS, GAICD, PET/CT Head, Cancer Imaging; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC); Peter MacCallum Cancer Centre, Melbourne; and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia
8:15 am Q & A
8:17 am Total-Body PSMA-PET vs. Short-Axial Field-of-View Conventional PSMA-PET in Patients with Biochemical Recurrence
Andrea Di Giorgio, MD, Nuclear Medicine Unit – University of Bologna, and University of Bologna Medical Center, Italy
.
8:27 am Q & A
8:29 am Micro-Ultrasound in Prostate Cancer: Role in Biopsy-Naive Patients, Decisions to Biopsy, and Active Surveillance
Adam Kinnaird, MD, PhD, Frank and Carla Sonjonky Chair of Prostate Cancer Research, Departments of Surgery, Oncology, Radiology and Diagnostic Imaging, University of Alberta, Canada
8:39 am Q & A
8:41 am Topic 1B: Clinical and Prognostic Implications of Cancer Visibility on Imaging
8:41 am Radiologic Perspective
Sungmin Woo, MD, PhD, Assistant Professor, Department of Radiology, NYU Grossman School of Medicine
8:51 am Q & A
8:53 am Urologic Perspective: Genomics and Natural History of MRI Invisible vs Visible Cancers
Laurence Klotz, MD
9:03 am Q & A
9:05 am Topic 1C: Novel and Emerging Pathological Factors in Localized and Recurrent Prostate Cancer
Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago
.
9:15 am Q & A
9:17 am Topic 1D: ProQuant Update – Gleason Pattern 4 for Risk Stratification
Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center
.
9:27 am Q & A
9:29 am Topic 1E: Integration of MRI with Histology, Genomics, and Proteomics
Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
9:39 am Q & A
9:41 am – 10:00 am Panel Discussion: Multiomics – Moderators and Speakers
10:00 am – 10:30 am COFFEE BREAK
10:30 am SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF (TBC)
Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign
Jane Nguyen, MD, PhD, Assistant Professor of Pathology at the Case Western Reserve University/ Lerner College of Medicine; Director of Genitourinary Pathology; Staff Pathologist in the Diagnostics Institute, Department of Pathology and Laboratory Medicine at the Cleveland Clinic
10:30 am Topic 2: Year in Review – Emerging Advances in Diagnosis and Treatment
Matthew Cooperberg, MD, MPH (TBC)
10:40 am Q & A
10:42 am Topic 3: Beyond the Grade: Histology‑Driven Risk Stratification in Prostate Cancer
Jane Nguyen, MD, PhD
10:52 am Q & A
10:54 am Topic 4: The Future of PSMA PET Imaging
Ashley E. Ross, MD, PhD, Associate Professor of Urology and Clinical Director, Polsky Urologic Oncology Center, Northwestern Feinberg School of Medicine. Sponsored by Blue Earth Diagnostics.
11:04 am Q & A
11:06 am Topic 5: Integration of Precision Diagnosis and Precision Treatment
11:06 am Topic 5A: Integrated Diagnostics (Radiogenomics) for Active Surveillance, Surgical and Radiation Treatment
Sanoj Punnen, MD, MAS, MBA, Professor of Urology, and Vice Chair of Research, Desai Sethi Urology Institute; and Assistant Director of Clinical Research and Cancer Control Research Program Co-Lead, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine
11:16 am Q & A
11:18 am Topic 5B: Image-Guided, Minimally-Invasive Focal Treatment: Emerging Role in Patient Management
John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
11:28 am Q & A
11:30 am Topic 5C: Human-AI Interaction in Prostate Cancer Diagnosis
Evis Sala, MD, PhD, FRCR, FRCP, Professor of Radiology, Università Cattolica del Sacro Cuore, Rome, Italy
11:40 am Q & A
11:42 am Topic 6: Optimal Management of Patients Presenting with Locally Advanced Prostate Cancer in 2026
Raja B. Khauli, MD
11:52 am Q & A
11:54 am Topic 7: Recurrent Disease
11:54 am Topic 7A: Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?
Giancarlo Marra, MD, Consultant Urologist and Assistant Professor, Division of Urology, AOU Citta Della Salute e Della Scienza and University of Turin, Italy
12:04 pm Q & A
12:06 pm Topic 7B: NCI Working Group Recommendations on Biomedical Cancer Recurrence
David Einstein, MD, Assistant Professor, Harvard Medical School, and Attending Physician, Beth Israel Deaconess Medical Center Genitourinary Medical Oncology Program
12:16 pm Q & A
12:18 pm Topic 7C: Clinical Role of PET/MRI in Biochemical Recurrence
Hong Song, MD, PhD, Assistant Professor, Nuclear Medicine/Radiology, Stanford University (TBC)
12:28 pm Q & A
12:30 pm – 12:50 pm Panel Discussion: Integration of Precision Diagnosis and Treatment
12:50 pm – 2:15 pm LUNCH BREAK
2:15 pm SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Moderators:..
Steven Eric Finkelstein, MD, DABR, FACRO, National Director of the Center of Advanced Radiation Excellence (CARE) and Director, Radiation Oncology Research, Associated Medical Professionals / US Urology, Syracuse, NY; and Board of Chancellors and Chair of Education Committee, American College of Radiation Oncology (ACRO)
Katherine Ferrara, PhD, Professor and Division Chief, Molecular Imaging Program, Stanford University (TBC)
Raluca Mititelu, MD, PhD, Lecturer, University of Medicine and Pharmacy Carol Davila Central University Emergency Military Hospital Bucharest, Romania
David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program
2:15 pm Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
2:15 pm Topic 1A: Best Practices for Clinical Trials in Patients with Advanced Prostate Cancer: Recommendations of the Prostate Cancer Working Group 4
David Nanus, MD
2:25 pm Q & A
2:27 pm Topic 1B: The Earlier Use of Radio Pharmaceuticals in Prostate Cancer
Marc B. Garnick, MD, Director of Cancer Community Services, BIDMC; Gorman Brothers Professor of Medicine at Harvard Medical School; and Editor-in-Chief, Harvard Medical School Prostate Disease Report
2:37 pm Q & A
2:39 pm Topic 1C: Immunotherapy – Review and Update
Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment
2:49 pm Q & A
2:51 pm Topic 1D: AI and Sequencing of Treatment
Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors
3:01 pm Q & A
3:03 pm Topic 1E: Novel Systemic Treatment: Recent Advances and Future Directions in Targeted Treatment:
Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University (TBC)
3:45 pm Q & A
3:50 pm – 4:20 pm Panel Discussion: Standard and Emerging Treatment
4:20 pm Topic 2: Molecular Imaging and Theranostics
Guest Moderator
Akram Al-Ibraheem, MD, Chairman, Department of Nuclear Medicine & PET/CT; Director, Nuclear Medicine Training Programs; and Head, Thyroid Cancer Multidisciplinary Team, King Hussein Cancer Center; President, Asia-Oceania Federation of Nuclear Medicine & Biology (AOFNMB); and President, Jordanian Society of Nuclear Medicine (JOSNM), Amman, Jordan
4:20 pm Topic 2A: PSMA-PET Metrics for Outcome Prediction in Patients with mCRPC
Sungmin Woo, MD, PhD
4:30 pm Q & A
4:32 pm Topic 2B: Radiologic Perspective on Integration of Molecular Imaging and Treatment
Andrei Iagaru, MD, Professor of Radiology and Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program, Stanford University
4:42 pm Q & A
4:44 pm Topic 2C: Response Assessment with PSMA PET: Where We Stand and What Can be Achieved?
Vikas Prasad, MD, PhD, Associate Professor of Radiology, Director of Clinical Theranostics, Center for Clinical Theranostics Research, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology; and Co-Chair, Theranostics Program, Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
4:54 pm Q & A
4:56 pm Topic 2D: Emerging Radioligand Therapy and Prostate Cancer
Ilya Gipp, MD, PhD (TBC)
5:06 pm Q & A
5:08 pm – 5:30 pm Panel Discussion: Molecular Imaging and Theranostics
5:30 pm – 6:30 pm General Discussion: Speakers, Moderators
8:00 am SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
Moderators:
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
Giovanni Lughezzani, MD, Staff Physician, Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (MI), and Associate Professor, Humanitas University, Milan, Italy
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
8:10 am Topic 1: Overview of Focal Treatment
Mark Emberton, MD
8:20 am Q & A
8:22 am Topic 2: Current Clinical Trials
8:22 am Urologic Perspective: Clinical Trials in Focal Treatment at NIH and Emerging Role of Intraprostatic Drug Delivery
Peter Pinto, MD, National Institutes of Health, Director of the Urologic Oncology Fellowship Program at the National Cancer Institute
8:32 am Q & A
8:34 am Radiologic Perspective: Multicentre Trials on Focal Therapy
Jurgen Futterer, MD, PhD,Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen; and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands
8:44 am Q & A
8:46 am Topic 3: AI and Focal Treatment – Quantitative MRI Reading, AI Derived Algorithms for ECE/BCR, and AI Use in MRI Directed Treatment of Prostate Cancer
Victoria Bird, MD, President and Founder of Urologic Integrated Care, Gainesville, FLA; Staff Urologic Surgeon, HCA Florida North Florida Hospital; CEO, Urology Division, Research Group, National Medical Association; and Former Affiliate Professor of Engineering, Biomedical Engineering, College of Engineering, and Former Assistant Professor, Department of Urology, College of Medicine, University of Florida
8:56 am Q & A
8:58 am Topic 4: Current State of Irreversible Electroporation (IRE) and Imaging in Prostate Cancer Focal Therapy
Professor Phillip Stricker M.B., B.S(N.S.W.)(Hons), F.R.A.C.S. AO, Conjoint Professor, UNSW and Western Sydney University; Chairman, Department of Urology, St Vincents Campus; Director, St Vincents Prostate Cancer Research Centre; and Emeritus Fellow Garvan Institute
9:08 am Q & A
9:10 am Topic 5: Is Focal Treatment Appropriate for High-Risk Prostate Cancer?
Xiaosong Meng, MD, PhD, Dedman Family Scholar in Clinical Care, Assistant Professor, Department of Urology, UT Southwestern Medical Center
9:20 am Q & A
9:22 am Topic 6: Comparative Analysis and Clinical Utility of the Current Modalities in Therapeutic Ablation for Prostate Cancer
Alessandro Marquis, MD, FEBU, Urology Clinic, Department of Surgical Sciences, Molinette Hospital and University of Turin
9:32 am – 9:50 am Panel Discussion
9:50 am – 10:10 am COFFEE BREAK
10:10 am Topic 7: Addressing Fundamental Challenges in Clinical Evaluation, Acceptance and Adoption of Image-Targeted Treatment- Perspective from the AdMeTech Foundation’s International Working Group
10:10 am Review and Update – Imaging for Improving Post-Ablation Assessment and Developing Short-Term Patient Outcomes
Faina Shtern, MD
10:20 am Current Approaches to MRI Reporting After Focal Treatment
Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
10:30 am Q & A
10:32 am The Ablation Site Imaging (AIM) Multicenter Diagnostic Accuracy Study of MRI After Focal Therapy
Alexander Light, MBBS, MRCS, NIHR Doctoral Fellow and Urology Registrar, Imperial Prostate, Imperial College London
10:42 am – 10:52 am Discussion
Led By:
Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, Honorary Consultant Radiologist, University College London Hospitals
Sangeet Ghai, MD, Professor and Trachtenberg Haque Chair in Image Guided Prostate Therapy Research, Director of Research, Joint Department of Medical Imaging, University Health Network – Mt Sinai Hospital – Women’s College Hospital, University of Toronto, Canada (TBC)
10:52 am A New Scoring System for PSMA Imaging and PSMA/MRI Integration for Patient Evaluation after Focal Treatment: Development and Preliminary Data
Giovanni Lughezzani, MD
11:02 am Q & A
11:04 am – 11:30 am Panel on MRI Reporting Post Focal Treatment – Rationale, Background, & Recommendations
Led By:
Daniel Margolis, MD
11:30 am – 12:00 pm Panel on Molecular Imaging Post Focal Treatment – Rationale, Background, Emerging Data, and Next Steps
Led By:
Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland
Andrea Di Giorgio, MD
12:00 pm – 12:30 pm GENERAL DISCUSSION
12:30 pm – 1:30 pm LUNCH BREAK
1:30 pm KEYNOTE PRESENTATION: We Still Don’t Understand the Prostate Cancer Genome: Why Not?
Keynote Speaker:
Paul Boutros, PhD, MBA
1:45 pm Q & A
2:00 pm – 2:30 pm PRESENTATION OF WINNING ABSTRACTS
2:30 pm – 4:00 pm GENERAL DISCUSSION
4:00 pm ADJOURN